GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Quantum BioPharma Ltd (XCNQ:QNTM) » Definitions » Change In Payables And Accrued Expense

Quantum BioPharma (XCNQ:QNTM) Change In Payables And Accrued Expense : C$2.34 Mil (TTM As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Quantum BioPharma Change In Payables And Accrued Expense?

Quantum BioPharma's Change In Payables And Accrued Expense for the quarter that ended in Sep. 2024 was C$1.58 Mil. It means Quantum BioPharma's Accounts Payable & Accrued Expense increased by C$1.58 Mil from Jun. 2024 to Sep. 2024 .

Quantum BioPharma's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was C$2.75 Mil. It means Quantum BioPharma's Accounts Payable & Accrued Expense increased by C$2.75 Mil from Dec. 2022 to Dec. 2023 .


Quantum BioPharma Change In Payables And Accrued Expense Historical Data

The historical data trend for Quantum BioPharma's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quantum BioPharma Change In Payables And Accrued Expense Chart

Quantum BioPharma Annual Data
Trend Aug15 Aug16 Aug17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Payables And Accrued Expense
Get a 7-Day Free Trial Premium Member Only 2.00 1.15 4.61 -0.95 2.75

Quantum BioPharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Change In Payables And Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.75 0.77 -1.42 1.41 1.58

Quantum BioPharma Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$2.34 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Quantum BioPharma Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Quantum BioPharma's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Quantum BioPharma Business Description

Industry
Traded in Other Exchanges
Address
199 Bay Street, Suite 4000, Toronto, ON, CAN, M5L 1A9
Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.